Core Viewpoint - Zhejiang Dongfang (600120.SH) announced the establishment of the Dongfang Zheyao Fund, with a total fundraising target of 500 million yuan [1] Group 1: Fund Structure - The fund will be managed by Dongfang Chanrong, a wholly-owned subsidiary of Zhejiang Dongfang, in collaboration with Bank of China Asset Management, High-tech Jin Investment, and Zhejiang Pharmaceutical Group [1] - Dongfang Chanrong will act as the controlling shareholder, while Zhejiang Pharmaceutical Group's wholly-owned subsidiary, Hanting Capital, will co-establish a new pharmaceutical fund management company [1] Group 2: Investment Contributions - Bank of China Asset Management's wholly-owned subsidiary, Bank of China Capital Private Fund Management (Beijing) Co., Ltd. will serve as the second general partner (GP2) [1] - The investment contributions from limited partners include: - Chanrong Huiying: 119.2 million yuan (23.84%) - Zhejiang Pharmaceutical Group: 29.8 million yuan (5.96%) - Bank of China Asset Management: 149 million yuan (29.8%) - High-tech Jin Investment's subsidiary, Hangzhou High-tech (Rights Protection) Venture Capital Co., Ltd.: 200 million yuan (40%) [1]

Core Viewpoint - Zhejiang Dongfang (600120.SH) announced the establishment of the Dongfang Zheyao Fund, with a total fundraising target of 500 million yuan, aimed at investing in the pharmaceutical sector [1] Group 1: Fund Structure - Dongfang Chanyun, a wholly-owned subsidiary of Zhejiang Dongfang, will act as the fund manager [1] - The fund will be jointly established with partners including Bank of China Asset Management, High-tech Jin Investment, and Zhejiang Pharmaceutical Group [1] - The fund management company will be a joint venture between Dongfang Chanyun and a wholly-owned subsidiary of Zhejiang Pharmaceutical Group, Hanting Capital [1] Group 2: Capital Contributions - The total fundraising scale is set at 500 million yuan, with various partners contributing different amounts [1] - Limited partners include: - Chanyun Huiying: 119.2 million yuan (23.84%) - Zhejiang Pharmaceutical Group: 29.8 million yuan (5.96%) - Bank of China Asset Management: 149 million yuan (29.8%) - High-tech Jin Investment's subsidiary, Hangzhou High-tech Venture Capital: 200 million yuan (40%) [1]